Cargando…

Alternative Checkpoints as Targets for Immunotherapy

PURPOSE OF REVIEW: Immunotherapy has shown an unprecedented response in treatment of tumors. However, challenges such as lack of cytotoxic lymphocytes to mount an immune response or development of resistance to therapy can limit efficacy. Here, we discuss alternative checkpoints that can be targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Pant, Ayush, Medikonda, Ravi, Lim, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608303/
https://www.ncbi.nlm.nih.gov/pubmed/33141349
http://dx.doi.org/10.1007/s11912-020-00983-y
_version_ 1783604809308307456
author Pant, Ayush
Medikonda, Ravi
Lim, Michael
author_facet Pant, Ayush
Medikonda, Ravi
Lim, Michael
author_sort Pant, Ayush
collection PubMed
description PURPOSE OF REVIEW: Immunotherapy has shown an unprecedented response in treatment of tumors. However, challenges such as lack of cytotoxic lymphocytes to mount an immune response or development of resistance to therapy can limit efficacy. Here, we discuss alternative checkpoints that can be targeted to improve cytotoxic lymphocyte function while harnessing other components of the immune system. RECENT FINDINGS: Blockade of alternative checkpoints has improved anti-tumor immunity in mouse models and is being tested clinically with encouraging findings. In addition to modulating T cell function directly, alternative checkpoints can also regulate activity of myeloid cells and regulatory T cells to affect anti-tumor response. SUMMARY: Combination of immune checkpoint inhibitors can improve treatment of tumors by activating multiple arms of the immune system.
format Online
Article
Text
id pubmed-7608303
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-76083032020-11-05 Alternative Checkpoints as Targets for Immunotherapy Pant, Ayush Medikonda, Ravi Lim, Michael Curr Oncol Rep Immuno-oncology (RM Bukowski and JH Finke, Section Editors) PURPOSE OF REVIEW: Immunotherapy has shown an unprecedented response in treatment of tumors. However, challenges such as lack of cytotoxic lymphocytes to mount an immune response or development of resistance to therapy can limit efficacy. Here, we discuss alternative checkpoints that can be targeted to improve cytotoxic lymphocyte function while harnessing other components of the immune system. RECENT FINDINGS: Blockade of alternative checkpoints has improved anti-tumor immunity in mouse models and is being tested clinically with encouraging findings. In addition to modulating T cell function directly, alternative checkpoints can also regulate activity of myeloid cells and regulatory T cells to affect anti-tumor response. SUMMARY: Combination of immune checkpoint inhibitors can improve treatment of tumors by activating multiple arms of the immune system. Springer US 2020-11-03 2020 /pmc/articles/PMC7608303/ /pubmed/33141349 http://dx.doi.org/10.1007/s11912-020-00983-y Text en © Springer Science+Business Media, LLC, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Immuno-oncology (RM Bukowski and JH Finke, Section Editors)
Pant, Ayush
Medikonda, Ravi
Lim, Michael
Alternative Checkpoints as Targets for Immunotherapy
title Alternative Checkpoints as Targets for Immunotherapy
title_full Alternative Checkpoints as Targets for Immunotherapy
title_fullStr Alternative Checkpoints as Targets for Immunotherapy
title_full_unstemmed Alternative Checkpoints as Targets for Immunotherapy
title_short Alternative Checkpoints as Targets for Immunotherapy
title_sort alternative checkpoints as targets for immunotherapy
topic Immuno-oncology (RM Bukowski and JH Finke, Section Editors)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608303/
https://www.ncbi.nlm.nih.gov/pubmed/33141349
http://dx.doi.org/10.1007/s11912-020-00983-y
work_keys_str_mv AT pantayush alternativecheckpointsastargetsforimmunotherapy
AT medikondaravi alternativecheckpointsastargetsforimmunotherapy
AT limmichael alternativecheckpointsastargetsforimmunotherapy